Effect of administration add on of Rifaximin on portal hypertension of patients with liver cirrhosis and esophageal varices in standard therapy with propranolol - ERASE study

Clinica Medica 50 个研究点目标入组 60 人开始时间: 2014年10月24日最近更新: 2018年3月19日

试验速览

暂无简介。

•1) Diagnosis of liver cirrhosis (based on clinical, biochemical and radiological criteria with or without liver biopsy)
•2) Presence of esophageal varices at high risk of bleeding
•3) HVPG> 12 mmHg.
•4) previous treatment with non-selective beta blockers
•5) 19=age=75
•6) Informed Consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•1) Patients already treat with beta blockers and then in the secondary prophylaxis for rebleeding
•2) Treatment with systemic antibiotics and / or non-absorbable intestinal antibiotics in the previous two weeks
•3) Bacterial infection, spontaneous bacterial peritonitis
•4) overt hepatic encephalopathy in the last week
•5) Gastrointestinal bleeding in act, or in the lastweek
•6) active alcoholism or drug abuse in last 3 weeks
•7) Acute Alcoholic Hepatitis
•8) Hepatocellular carcinoma or other neoplasm
•9) significant coronary artery disease (angina NYHA III / IV), congestive heart failure (NYHA III / IV), relevant cardiomyopathy, history of myocardial infarction within the last 12 months
•10) Contraindications to the administration of beta blockers; allergy to Rifaximin
•11) Pregnancy or lactation
•12) Refusal to participate

发起方

Clinica Medica 5